Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients With Active Psoriatic Arthritis: Results from a Phase 2 Trial. J of Skin 2024, 8 (2), s383. https://doi.org/10.25251/skin.8.supp.383.